FY2025 · ended Dec 31, 2025 · Revenue $37.06M, +4.1% YoY · Filed Mar 30, 2026
Cytosorbents Corporation (CTSO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $37.1 million and a net loss of $8.2 million. Free cash flow was -$12.5 million. As of Jun 30, 2026 it held $4.4 million in cash and investments and $29.4 million in total debt.
Revenue (TTM)
$37.22M
+3.1% vs year-ago TTM
Net income (TTM)
$-18.21M
-84.6% vs year-ago TTM
Operating cash flow (TTM)
$-9.15M
+6.5% vs year-ago TTM
Free cash flow (TTM)
$-9.30M
EPS (TTM)
$-0.30
-84.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
62.70M
+0.3% vs prior year
Net cash
$-25.01M
as of Jun 30, 2026
Operating margin
-34.7%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CTSO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1175151
- Former names
- MedaSorb Technologies CORP (until Apr 15, 2010); GILDER ENTERPRISES INC (until Jul 24, 2006)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M |
| Operating income | -$14.7M | -$16.5M | -$31.9M | -$31.5M | -$22.7M |
| Net income | -$8.2M | -$20.7M | -$29.2M | -$32.8M | -$24.6M |
| Diluted EPS | -$0.13 | -$0.38 | -$0.65 | -$0.75 | -$0.57 |
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M | -$14.0M |
| Free cash flow | -$12.5M | -$14.7M | -$22.2M | -$34.3M | -$17.6M |
| Total assets | $44.2M | $47.4M | $53.0M | $63.2M | $89.5M |
| Total liabilities | $38.3M | $36.3M | $29.5M | $27.9M | $26.9M |
| Stockholders' equity | $5.9M | $11.1M | $23.5M | $35.4M | $62.6M |
| Cash and investments | $6.2M | $3.3M | $14.1M | $22.1M | $52.1M |
| Total debt | $29.1M | $26.9M | $18.3M | $18.3M | $13.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 23, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 14, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 7, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 977 Cytosorbents Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.